In parallel, we studied APP metabolite levels in the patient samples and we observed a trend to decrease of sAPPα levels in the CSF of ALS patients and a significant increase in sAPPα levels in serum from patients. This evidence concerns the gene APP and amyotrophic lateral sclerosis.